US/UK/Canada

Share

Pick a time period -
Tags ( Active)

Pergamum announces final data from Phase I/II study of LL-37 in patients with chronic leg ulcers

STOCKHOLM – October 10, 2013. Pergamum AB, which is a portfolio company of Karolinska Development AB, announced today that it has finalized the Clinical Study Report of a randomized Phase I/II trial of LL-37 for treatment of venous leg ulcers. Patients treated with LL-37 had a statistically significant improved healing rate compared with placebo and no safety or tolerability concerns were noted, confirming the positive preliminary data reported in July this year.Chronic leg ulcers are often defined as those that fail to heal after six weeks or more of appropriate treatment. Venous leg

Karolinska Development presents today at the 2013 Stifel Healthcare Conference in Boston

STOCKHOLM – September 12, 2013. Karolinska Development announces that Dr Torbjörn Bjerke, CEO, will present at the 2013 Stifel Healthcare Conference in Boston, MA, today at 10.55 AM EDT (4.55 PM CEST). The presentation includes an update of Karolinska Development and its portfolio companies and can be accessed live and as a replay on www.karolinskadevelopment.com.For further information, please contact:Torbjörn Bjerke, CEO, Karolinska Development ABPhone: +46 (0)72 744 41 23, e-mail: torbjorn.bjerke@karolinskadevelopment.com Benjamin Nordin, IRO, Karolinska Development ABPhone: +46

Lipidor reports positive clinical Phase I/II data in psoriasis

STOCKHOLM – August 27, 2013. Today Lipidor announced positive results from a Phase I/IIa study investigating the efficacy and tolerability of its AKVANO®/calcipotriol spray formulation for the treatment of psoriasis vulgaris, the most common form of psoriasis. Karolinska Development owns 50% of Lipidor.“The positive study results represents an important milestone for Lipidor in its efforts to develop a product with equivalent clinical efficacy compared to market leading calcipotriol-only topical treatments, and with superior cosmetic qualities and greater ease of use, thereby, improving

Purchase of own shares to cover social security fees related to incentive program

STOCKHOLM - August 22, 2013. The Board of Directors of Karolinska Development has decided – within the authorization from the Annual General Meeting on May 14, 2013 – to purchase a maximum of 93,685 shares of Series B.The purchase will be made from August 28, 2013 to May 13, 2014, which is the day before the Annual General Meeting 2014. The purchase of shares shall take place on NASDAQ OMX Stockholm and may only occur at a price within the share price interval registered at that time. The share price interval is the price interval between the highest buying price and the lowest selling

Karolinska Development AB (publ) ― Interim report January - June 2013

STOCKHOLM – August 22, 2013. Karolinska Development AB (publ) announces publication of its Interim report January-June, 2013. A conference call will be held today at 15.00 CET. Participant access numbers: SE: +46 (0) 8 506 307 79, UK: +44 (0) 1452 555 131, or US: +1 866 682 8490. The full report and a link to the webcast are available on the company's website.Torbjörn Bjerke, CEO, comments: ”The progress in Karolinska Development’s active company portfolio remains strong. Since the first quarter 2013, positive clinical data have been presented for four projects. Our focus on business

Pharmanest meets all efficacy and safety end points in Phase II study of SHACT

STOCKHOLM – August 1, 2013. Pharmanest AB announced today positive results from a Phase II-study investigating the efficacy and tolerability of SHACT. The data show that SHACT is effective in reducing pain in connection with intrauterine device insertion. Karolinska Development owns 63% of Pharmanest*.Every year, millions of women around the world experience pain and discomfort during IUD insertion (intrauterine contraception). There are few treatment options with proven efficacy and safety available to these women. SHACT is a product based on an innovative formulation of lidocaine, a well-

Oss-Q completes financing, initiates clinical study and changes name to OssDsign

STOCKHOLM, July 15, 2013. Oss-Q AB, a Swedish medtech company focusing on implants for bone replacement, has received SEK 13.7m through a rights issue and will now initiate a clinical trial with OssDsign Cranio PSI, its implant for skull reconstruction. In connection with these important advances, the company will change its name to OssDsign AB. Karolinska Development invested SEK 6.8m in the rights issue, increasing its ownership in OssDsign AB from 16% to 26%*.After closing of a SEK 13.7m financing round, OssDsign has taken another important step by initiating a clinical multi-center

Pergamum reports positive preliminary efficacy results from a Phase I/II study of LL-37 in patients with chronic leg ulcers

STOCKHOLM – July 4, 2013. Pergamum AB, a portfolio company of Karolinska Development AB, announced today that the primary safety and tolerability end-point was met in the randomized Phase I/II trial of LL-37 for treatment of venous leg ulcers. The data also show that patients treated with LL-37 had a statistically significant improved healing rate compared with placebo.In a double blind multicenter study, 34 patients with venous leg ulcers received either placebo or one of three different doses of LL-37. The primary objective of the trial was to assess the safety and tolerability of

Karolinska Development initiates collaborations with Ospedale San Raffaele and Medical University of Graz

STOCKHOLM – June 27, 2013. Two more world class research centers are teaming up with Karolinska Development. Deal flow agreements have been signed with the Italian university hospital Ospedale San Raffaele and the Medical University of Graz in Austria, which enable Karolinska Development to identify investment opportunities among life science innovations emanating from these leading medical research institutions.Karolinska Development will assist in the evaluation and assessment of new innovations from each institution, and has the opportunity to invest in commercially attractive projects.

Pergamum reports positive follow-up data from a Phase II clinical trial of PXL-01 for prevention of post-surgical adhesions

STOCKHOLM – June 27, 2013. Pergamum AB announced today that several end-points were met in a randomized Phase II trial of PXL-01 for prevention of post-surgical adhesions. Karolinska Development AB is the majority owner of Pergamum.Many patients undergoing hand surgery suffer from debilitating scar formation, which reduces the range of motion and complicates daily activities. PXL-01 is a novel therapeutic peptide that has been developed with the purpose to reduce the formation of obstructing scars and restore mobility and function. Follow-up data from the Phase II clinical trial of PXL-

Karolinska Development invests in Forendo Pharma

STOCKHOLM – June 25, 2013. Karolinska Development AB announced today that it has invested in Forendo Pharma Oy, a new drug development company based in Finland, together with Novo Seeds and Finnvera. The stepwise funding commitments, together with previous funding from Tekes, are expected to reach EUR 10m over a period of three years, of which Karolinska Development will invest up to EUR 3.0m.Karolinska Development today announced that it will invest in Forendo Pharma Oy, a company based on research from the University of Turku that is developing novel treatments for endometriosis and for

Athera and Boehringer Ingelheim enter into an option agreement on a novel therapy for Atherosclerosis

STOCKHOLM, SWEDEN – June 19, 2013. Athera Biotechnologies AB today announced that it has entered into an option agreement with Boehringer Ingelheim International GmbH on a novel preclinical antibody program, whereby Athera grants to Boehringer Ingelheim an exclusive option to acquire the entire program. Karolinska Development AB owns 65% of Athera Biotechnologies AB.Athera’s fully-human monoclonal antibody is intended for the treatment of patients with cardiovascular disease, who are at an increased risk of secondary events and death. Pursuant to the terms of the option agreement, Athera

EU grants EUR 6m to the clinical development of Athera´s cardiovascular disease antibody therapy

STOCKHOLM, SWEDEN – June 17, 2013. Athera Biotechnologies AB today announced that future development costs of its fully human antibody PC-mAb up until proof-of-concept will be co-funded by the European Union’s Seventh Framework Programme for Research (FP7) through a collaborative research grant. Karolinska Development AB owns 65% of Athera Biotechnologies AB.Athera’s fully human monoclonal antibody PC-mAb is targeting phosphorylcholine and is being developed for the treatment of patients with an increased risk of atherosclerosis related cardiovascular events and death. This includes

First patient dosed in the Phase I/II study of Umecrine Mood’s candidate drug for premenstrual dysphoric disorder

STOCKHOLM – May 23, 2013. Umecrine Mood AB announced today that dosing has been initiated in a randomized Phase I/II study of UC1010 for the treatment of patients with premenstrual dysphoric disorder (PMDD). Umecrine Mood is part of the Karolinska Development portfolio.Most women experience some form of symptoms the days before menstruation but in about five percent of young and middle-aged women, the symptoms are so severe that they are considered to be suffering from PMDD. This means that the symptoms in a debilitating way affect daily life and relationships to other people. "The

Karolinska Development´s Annual General Meeting 2013

STOCKHOLM - May 15, 2013. At the Annual General Meeting of Karolinska Development AB held May 14, 2013, the following resolutions were passed, in accordance with the presented proposals:Profit and loss statement: It was resolved to adopt the profit and loss statement and the balance sheet and the consolidated profit and loss statement and the consolidated balance sheet. Appropriation of the result: It was resolved to approve the allocation of the result, proposed by the Board and the CEO: in total SEK 1,228,273,447 is to be allocated as follows: to be carried forward SEK 1,228,273,447.

Karolinska Development AB (publ) - Interim report January - March 2013

STOCKHOLM – May 10, 2013. Karolinska Development AB (publ) announces publication of its Interim report January-March, 2013. A conference call will be held today at 14.00 CET. Participant access numbers: SE: +46 (0)8 506 307 79, UK: +44 (0) 1452 555 131, or US: +1 866 682 8490. The full report and a link to the webcast are available on the company's website.Torbjörn Bjerke, CEO, comments: “During the first quarter, Karolinska Development finalized the strategically important deal with Rosetta Capital, in which a minor part of the portfolio was sold at a premium of 23 percent compared to our

Karolinska Development - Interim report January - March, invitation to conference call Friday, May 10

STOCKHOLM – May 7, 2013. Karolinska Development will publish its Interim report for January – March 2013 on Friday, May 10, 2013. The company will also host a conference call and an on-line presentation on the same day at 14.00 CET.Please dial in at the following number a few minutes before the start of the conference call: · From Sweden: +46 (0)8 506 307 79 · From the US: +1 866 682 8490 · From the UK: +44 (0) 1452 555 131 The presentation will also be webcasted and can be accessed from the following web address:http://storm.zoomvisionmamato.com/player/karolinska_

Pergamum announces last visit of last patient in a Phase I/II trial of a potential new treatment for hard-to-heal wounds

STOCKHOLM – April 19, 2013. Pergamum AB announced today that the company has reached last-patient-last-visit (LPLV) in a randomized Phase I/II trial of LL-37 for the treatment of hard-to-heal venous leg ulcers. Karolinska Development AB is the majority owner of Pergamum.Non-healing wounds are a sizable burden for the individual patient and for the health care system. Today, there are more than 15 million patients globally, and virtually no medical progress has been made over the last few decades in regard to pharmacological treatments. "LL-37 is a therapeutic peptide which contributes to

Karolinska Development’s Annual Report 2012 has been published

STOCKHOLM – April 12, 2013. Karolinska Development’s Annual Report 2012 has been published and is now available on www.karolinskadevelopment.com.For further information, please contact:Torbjörn Bjerke, CEO, Karolinska Development ABPhone: +46 (0)72 744 41 23, e-mail: torbjorn.bjerke@karolinskadevelopment.com Benjamin Nordin, IRO, Karolinska Development ABPhone: +46 (0)73 093 60 80, e-mail: benjamin.nordin@karolinskadevelopment.com TO THE EDITORS About Karolinska Development ABKarolinska Development aims to create value for patients, researchers, and investors by developing

Notice of Annual General Meeting of Karolinska Development AB (publ)

STOCKHOLM – April 11, 2013. The shareholders of Karolinska Development AB (publ), reg. no. 556707-5048, (“Karolinska Development” or the “Company”) are invited to the Annual General Meeting, on Tuesday 14 May, 2013, at 5 p.m. (CET), at Fogdevreten 2 A Solna, Sweden.Participation and notification of attendance A shareholder, who wishes to participate in the meeting, must (i) be recorded as shareholder (not nominee registered) in the share register held by Euroclear Sweden AB on Tuesday 7 May 2013, and (ii) notify Karolinska Development of his/her intention to attend the meeting, no

Bo Jesper Hansen proposed as new Chairman of the Board

STOCKHOLM - April 10, 2013. The Nomination Committee proposes Bo Jesper Hansen to be appointed Chairman of the Board of Karolinska Development at the Annual General Meeting on May 14, 2013.The Nomination Committee proposes election of Bo Jesper Hansen as new member of the Board at the 2013 AGM. The Nomination Committee further proposes that Bo Jesper Hansen will succeed Hans Wigzell as the new Chairman of the Board as of 1 October 2013. Hans Wigzell is proposed to remain as ordinary Board member from the corresponding date. The Nominating Committee believes that the smooth transition

Preliminary results of a Phase II study indicates that Axelar’s AXL1717 is efficacious in 2nd line treatment of patients with lung cancer

STOCKHOLM, April 2, 2013. Axelar AB, part of the Karolinska Development AB portfolio, announced today that preliminary interim results of its Phase II study AXL-003, indicates that AXL1717 is effective in treating patients with non-small cell lung cancer (NSCLC). Thus, the company assesses that it has sufficient data to guide further development of the drug, and will finalize the study with fewer patients than initially planned.Dr. Carl Harald Janson, CEO, Axelar AB“We are delighted to see the impact of AXL1717 in this difficult to treat patient population. The encouraging trial data

Karolinska Development and Rosetta Capital Announce the Closing of their SEK 220 Million Strategic Transaction

STOCKHOLM – March 8, 2013. Karolinska Development AB and the life science investor Rosetta Capital Limited (“Rosetta”) announced today that Rosetta Capital IV LP has now acquired the minority share in Karolinska Development’s holdings in 13 of its 25 portfolio companies for SEK 220 million, in line with the previous announcement on December 21, 2012.In February 2013, Karolinska Development transferred 13 of its portfolio company holdings to a new private holding company, KDev Investments AB. Late yesterday (CET), Rosetta acquired 7.33% of the common shares in KDev Investments AB for SEK 110

There are no items matching the current filter
There are no more items matching the current filter
Back to top

Media